---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-330599"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2026-08-03T20:15:24+00:00"
generated_at: "2026-08-03T20:17:52.767568+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "low"
source: SEC EDGAR
---

# Perspective Therapeutics updates corporate presentation highlighting 212Pb pipeline

## Summary
- Updated presentation includes ASCO 2026 data for VMT-α-NET in neuroendocrine tumors with 68 patients treated.
- VMT01 for melanoma shows preliminary anti-tumor activity at 3.0 mCi dose in ongoing Phase 1/2a.
- PSV359 targeting FAP-α for solid tumors is in Phase 1/2a with improved tumor retention.
- Company emphasizes 212Pb-based theranostic approach and direct-to-hospital delivery model.

## SEC filing metadata
- accession: 0001193125-26-330599
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2026-08-03T20:15:24+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312526330599/0001193125-26-330599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312526330599/catx-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-330599
- JSON: https://secwatch.observer/filing/0001193125-26-330599.json
- Plain text: https://secwatch.observer/filing/0001193125-26-330599.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.